Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians.

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians.

To complete the activity and claim free CME/NCPD, visit: https://i3health.com/mf

Additional Advances in Myelofibrosis Research and Clinical Trials With John Mascarenhas, MD

In this edition of Oncology Data Advisor celebrating Kidney Cancer Awareness Month Dr. Samuel Kareff, Dr. Waqas Haque, and Dr. Ulka Vaishampayan discuss the rising incidence of kidney cancer, warning signs and symptoms to look out for, environmental risk factors such as tobacco use, emerging treatment strategies using immunotherapy and adjuvant therapy, considerations for genetic testing, and the importance of clinical trial participation for bringing these new advances to the forefront of care.

Kidney Cancer Awareness Month: Discovering Clinical Strategies to Improve Outcomes

In this edition of the Oncology Data Fellows Forum in celebration of National Doctor's Day, Samuel Kareff, MD, MPH, and Matthew Hadfield, DO, discuss the highs and lows of working in this field and why it is important to take a moment to celebrate being a physician, your fellow physicians, and your patients.

National Doctor’s Day With Samuel Kareff, MD, MPH, and Matthew Hadfield, DO

Dr. Christopher Lieu, Associate Director of Clinical Research at the University of Colorado Cancer Center and Vice Chair of the National Comprehensive Cancer Network (NCCN), is currently serving as chair of i3 Health's online activity, live webinar, and meeting series, Hitting the Target in HER2-Positive Metastatic Colorectal Cancer. With numerous research advances occurring in this field during the past year, Dr. Lieu sat down with us again to share updates in targeted therapies for HER2-positive metastatic colorectal cancer and the evolving landscape of biomarkers under investigation for this disease.

Click the links below for Hitting the Target in HER2-Positive Metastatic Colorectal Cancer, an accredited CME/NCPD activity provided by i3 Health!

Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/hitting-the-target-in-her2-positive-metastatic-colorectal-cancer

Live Webinar Registration: https://www.i3health.com/course-information/Colorectal-Cancer-Webinar

Live or Virtual Meeting Series: https://www.i3health.com/live/hitting-the-target-in-her2-positive-metastatic-colorectal-cancer-1

Additional Advances in HER2-Positive Metastatic Colorectal Cancer Research: Christopher Lieu, MD

Adolescent and Young Adult (AYA) Cancer Awareness Week, April 1 to 5, 2024, is a time to shine a spotlight on adolescent and young adult cancer patients and survivors. To commemorate the week, Lauren Ghazal, Megan-Claire Chase, and Allison Rosen, all members of the Oncology Data Advisor Editorial Board, sat down for a conversation to highlight the issues that AYA cancer patients face, including fertility preservation and financial toxicity; the need to ensure that race, ethnicity, and sexual orientation are not overlooked when building welcoming support spaces for all patients; and the value of turning to the AYA community for support while also serving as your own best advocate.

AYA Cancer Awareness Week 2024

In this interview, Jason Mouabbi, MD, an Oncology Data Advisor Editorial Board Member and Assistant Professor in the Department of Breast Oncology at the University of Texas MD Anderson Cancer Center, sat down with Valerie Brutus, MD, FACS, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, and Elizabeth Stirling Craig, MD, Director of Microvascular Breast Reconstruction at St. Vincent's Medical Center of Hartford HealthCare, to discuss improving breast cancer surgical outcomes with lymphovenous bypass surgery.

Dr. Mouabbi engages Dr. Brutus and Dr. Craig in a thought-provoking discussion about lymphovenous bypass surgery: what it is, who qualifies for this procedure, its viability, what to expect from this procedure and its treatment process, and more about breast cancer surgical outcomes.

Improving Breast Cancer Surgical Outcomes With Lymphovenous Bypass

In this interview from the American Association for Cancer Research (AACR) 2024 Annual Meeting, Dr. Alankrita Taneja, third-year Hematology/Oncology Fellow at Roswell Park Cancer Institute and Oncology Data Fellows Forum Member, speaks with Dr. Sundar Jagannath, Professor of Medicine (Hematology and Medical Oncology) and Director of the Center of Excellence for Multiple Myeloma at the Mount Sinai Icahn School of Medicine and Tisch Cancer Institute. 

At the meeting, Dr. Jagannath presented results of the phase 1/2 LINKER-MM1 trial of linvoseltamab, a CD3-directed B-cell maturation antigen (BCMA) antibody under investigation for relapsed/refractory multiple myeloma. In this follow-up conversation, Dr. Jagannath shares further insights into the trial, including: 
•	The study design, which includes triple-class–refractory patients
•	The unique dosing schedule of linvoseltamab, which reduces the frequency of administration to improve patient convenience
•	The response, survival, and measurable residual disease (MRD) negativity outcomes demonstrated in the trial, including among high-risk patients
•	Management of side effects, including cytokine release syndrome (CRS), neutropenia, anemia, and infections
•	The future role of linvoseltamab in the treatment landscape for relapsed/refractory multiple myeloma as it advances through investigation
•	And more!

Linvoseltamab for Relapsed/Refractory Multiple Myeloma: Updates on LINKER-MM1 From AACR 2024

This April, Oncology Data Advisor is raising awareness for Esophageal Cancer Awareness Month. In this interview, Oncology Data Advisor Editorial Board and Fellows Forum members Dr. Joseph Kalis, Dr. Matthew Hadfield, and Dr. Samuel Kareff discuss rising trends, treatment advances, and emerging management strategies for esophageal cancer, including the following: 
•	The rising rate of adenocarcinoma in the context of pre-existing esophageal dysplasia and Barrett esophagus
•	Risk factors such as tobacco and alcohol
•	The roles of healthy eating and smoking cessation in esophageal cancer prevention 
•	How the rise of immunotherapies such as pembrolizumab, nivolumab, and trastuzumab have changed practice
•	This month’s approval of fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2 (HER2)–positive solid tumors
•	Lifestyle interventions such as following the Mediterranean diet and United States Preventive Services Task Force (USPSTF) exercise guidelines that can make maximize tolerability of therapy

Esophageal Cancer Awareness Month: Treatment Advances and Tools for Maximizing Tolerability

Last year, Brian Rubin, MD, PhD, Chair of Pathology and Laboratory Medicine and the Chief of Diagnostics at the Cleveland Clinic, served as co-chair for i3 Health's continuing medical education CME NCPD #virtualtumorboard: Multidisciplinary Management of Advanced Soft Tissue Sarcoma. 

In this interview, Dr. Rubin sat down with Oncology Data Advisor  to discuss updates in the treatment and management of soft tissue sarcoma, what to look forward for the future of treating sarcomas, and his passion for this field. Watch the interview now and complete the activity here: https://bit.ly/3tHGzni

Additional Advances in Soft Tissue Sarcoma With Brian Rubin, MD, PhD

In celebration of Head and Neck Cancer Awareness Month this April, Oncology Data Advisor Fellows Forum and Editorial Board Members Samuel Kareff, MD, MPH; Matthew Hadfield, DO; and Nagashree Seetharamu, MD, sat down to discuss the epidemiology of head and neck squamous cell carcinomas (HNSCC), the diagnostic and treatment process of HNSCC, including:
–Epidemiologic trends
–Geographic distribution
–Approved screening methods
–Novel treatment combinations
–Side effects and adverse events
–Survivorship
–And more!

Celebrating Head and Neck Cancer Awareness Month

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Additional Advances in Myelofibrosis Research and Clinical Trials With John Mascarenhas, MD

Oncology Data Advisor®

Related tracks